Pelago Bioscience enable successful Drug Discovery by providing physiologically relevant high quality Target Engagement data using the patented CETSA® method. We combine extensive commercial Drug Discovery experience with world leading fundamental basic scientific research.

Our focus is to deliver high quality target engagement data to our customers and partners, enabling faster development of better and more efficacious new drugs. By outsourcing your Target Engagement assays to us you reduce your risk and speed up project progression. We provide a flexible fee for service model and can also offer method sublicensing, tech transfer as well as consulting and risk shared collaborations.


Meet Us

Stockholm June 8

Biotech Hanse Forum. The Biotech Hanse Organisation aims at connecting people from the biotech and life-science sectors of Sweden and Germany. Read more

Berlin June 13-14

17th Drug Discovery Summit and 4th Discovery Chemistry & Drug Design Congress. Meeting agenda: ddx_summit17_berlin.pdf


Latest Posts


May 2016:

CETSA® and Pelago explained in 8 minutes

April 2016:

New publication on CETSA® HT

Pelagos CSO Daniel Martinez Molina and Pär Nordlund co-authors the very first paper on CETSA® HT screening, identifying novel binders of Thymidilate Synthase. You will find the publication here.

March 2016:

CETSA rules!

The CETSA® method is becoming a standard technique, it is being used routinely to demonstrate target engagement of small molecule's for a specific target in the living cell. Read the review in GEN Exclusives update.


December 2015:

Min Stora Dag

This year we are very proud and happy to donate our christmas gift to Min Stora Dag/My Special Day - a foundation who give special kids great memories. Merry Christmas!

November 2015:

Astra Zeneca collaboration

Our new strategic collaboration with AstraZeneca will further accelerate the development of CETSA® applications relevant for drug discovery. pressreleasepelagoaz.pdf

November 2015:

SWELife/Vinnova Grant

We have together with Karolinska Universitetssjukhuset been awarded a SWELife/Vinnova grant to start exploring CETSA® as an In Vitro Diagnostic tool in the validation of predictive biomarkers. swelifegrantpressrelease.pdf

October 2015:

Pfizer sub-licensing agreement

Pfizer Inc. and Pelago annouce that we have entered in to a sub-licensing agreement on the use of the CETSA™ method. Read the full statement here: pressreleasepbpfizer.pdf


September 2015:

Pelago enters a collaboration with Biovica

Pelago and Biovica announce our collaboration to develop a novel platform to enable development of new oncology drugs. Read more from the pressrelease